JAK Inhibitors in Practice

Episodes 1-5 of 5

• 

  RestartResume

  Tolerability of JAK Inhibitors Used in Dermatology

  RestartResume

  Tolerability of JAK Inhibitors Used in Dermatology

  JAK Inhibitors in Practice

  Tolerability of JAK Inhibitors Used in Dermatology

  • 

    

    Matthew J. Zirwas, MD

  • 

    

    Adelaide Hebert, MD

• 

  RestartResume

  Clinical Conversations: Risks vs Benefits of JAK Inhibitors

  RestartResume

  Clinical Conversations: Risks vs Benefits of JAK Inhibitors

  JAK Inhibitors in Practice

  Clinical Conversations: Risks vs Benefits of JAK Inhibitors

  • 

    

    Matthew J. Zirwas, MD

  • 

    

    Adelaide Hebert, MD

• 

  RestartResume

  Clinical Conversations: The Data for JAK Inhibitors in AD

  RestartResume

  Clinical Conversations: The Data for JAK Inhibitors in AD

  JAK Inhibitors in Practice

  Clinical Conversations: The Data for JAK Inhibitors in AD

  • 

    

    Brad Glick, DO, MPH

  • 

    

    Raj Chovatiya, MD, PhD

• 

  RestartResume

  Clinical Conversations: How JAK Inhibitors are Changing the AD Treatment Landscape

  RestartResume

  Clinical Conversations: How JAK Inhibitors are Changing the AD Treatment Landscape

  JAK Inhibitors in Practice

  Clinical Conversations: How JAK Inhibitors are Changing the AD Treatment Landscape

  • 

    

    Matthew J. Zirwas, MD

  • 

    

    Adelaide Hebert, MD

• 

  RestartResume

  Clinical Conversations: MOA of JAK Inhibitors in Dermatology

  RestartResume

  Clinical Conversations: MOA of JAK Inhibitors in Dermatology

  JAK Inhibitors in Practice

  Clinical Conversations: MOA of JAK Inhibitors in Dermatology

  • 

    

    Brad Glick, DO, MPH

  • 

    

    Raj Chovatiya, MD, PhD